For a patient with relapsed acute lymphoblastic leukemia whose blasts express CD20, can rituximab be used instead of the recommended salvage agents (blinatumomab or inotuzumab ozogamicin)?

No, rituximab should not be used instead of blinatumomab or inotuzumab ozogamicin for relapsed acute lymphoblastic leukemia

Rituximab is indicated for first-line treatment of CD20-positive B-ALL in combination with chemotherapy, not as salvage therapy for relapsed disease. The evidence clearly demonstrates that blinatumomab and inotuzumab ozogamicin are the appropriate targeted agents for relapsed/refractory ALL, with established efficacy in this specific clinical setting.

Why Rituximab Is Not Appropriate for Relapsed ALL

Indication Mismatch

The 2024 ESMO guidelines and FDA labeling establish rituximab's role specifically in newly diagnosed, first-line treatment of CD20-positive B-cell precursor ALL 1, 2. The drug label explicitly lists indications for various lymphomas and leukemias, but notably includes "mature B-cell acute leukemia (B-AL)" only in the context of previously untreated disease in combination with chemotherapy 2.

Evidence Base Is for Frontline Therapy

All major studies demonstrating rituximab's benefit in ALL evaluated its use during initial treatment:

• The MDACC study showed improved 3-year OS (75% vs 47%) when rituximab was added to hyper-CVAD in first-line therapy for patients <60 years with CD20-positive disease 1, 3
• The GMALL study achieved 94% CR rates and 90% MRD negativity by week 16 with rituximab during induction and consolidation 1
• The GRAALL randomized study demonstrated improved event-free survival with 16-18 rituximab infusions in frontline treatment 1

Limited Data in Relapsed Setting

The evidence for rituximab in relapsed ALL is extremely limited:

• One small pilot series of only 9 adult patients showed some activity when combined with chemotherapy, but this represents weak evidence 4
• A case series of just 3 pediatric patients is insufficient to establish efficacy 5
• These small studies cannot compete with the robust data supporting blinatumomab and inotuzumab ozogamicin

Why Blinatumomab and Inotuzumab Are Superior

Established Efficacy in Relapsed Disease

Blinatumomab (CD3/CD19 bispecific T-cell engager):

• Demonstrated superior outcomes in the phase III ECOG-ACRIN E1910 study with median OS not reached versus 71.4 months in controls (P=0.003) 1
• Achieves 80% MRD conversion from positive to negative in relapsed patients 1
• Specifically designed and approved for relapsed/refractory B-ALL 1

Inotuzumab ozogamicin (CD22-directed antibody-drug conjugate):

• FDA-approved specifically for relapsed or refractory CD22-positive B-ALL 6
• Demonstrated efficacy even after failure of blinatumomab and conventional chemotherapy 7
• Represents standard salvage therapy with established dosing and safety profiles 8

Mechanistic Advantages

• Blinatumomab engages the patient's own T cells to kill CD19-positive blasts through a novel mechanism distinct from rituximab's complement-dependent cytotoxicity 1
• Inotuzumab delivers cytotoxic calicheamicin directly to CD22-positive cells, providing targeted chemotherapy 7
• Both agents target different antigens (CD19, CD22) than rituximab (CD20), potentially addressing antigen heterogeneity in relapsed disease

Clinical Algorithm for Relapsed CD20-Positive B-ALL

1. Confirm relapse with bone marrow evaluation and immunophenotyping
2. Assess CD19 and CD22 expression on blasts (not just CD20)
3. First-line salvage: Choose between:
   • Blinatumomab if CD19-positive (most common scenario)
   • Inotuzumab ozogamicin if CD22-positive
4. Second-line salvage: Use the alternative agent if first salvage fails 8, 7
5. Bridge to transplant: Both agents can serve as effective bridges to allogeneic HSCT 1, 7

Critical Pitfalls to Avoid

Do not assume CD20 positivity alone justifies rituximab use in relapsed disease. While CD20 may be expressed, the evidence base, regulatory approvals, and clinical guidelines all support blinatumomab or inotuzumab as appropriate salvage agents 1, 9.

Do not extrapolate first-line data to the relapsed setting. The biology of relapsed ALL differs from newly diagnosed disease, with potential clonal evolution and treatment resistance mechanisms that rituximab monotherapy or combination with chemotherapy may not adequately address 9, 8.

Consider that rituximab could potentially be added to blinatumomab or inotuzumab-based regimens if CD20 remains highly expressed (≥20%), but this would be supplementary rather than replacement therapy, and lacks strong evidence 1.

The current standard of care, supported by the most recent 2024 ESMO guidelines, clearly positions blinatumomab and inotuzumab ozogamicin as the appropriate targeted therapies for relapsed B-ALL, with rituximab reserved for frontline treatment in combination with chemotherapy 1, 9.